Drug Trial Radar · NCT01380743
Drug-drug Interaction Study
Last checked: Nov 20, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Oct 31, 2011
Primary completion
Jan 4, 2013
Study completion Jan 4, 2013
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 27, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates drug-drug interactions between AT2220 (duvoglustat) and recombinant human alpha-glucosidase (rhGAA, also known as alglucosidase alfa) in participants with Pompe Disease.
Conditions
- Pompe Disease
Interventions
duvoglustatDrug
Single oral dose
rhGAADrug
Single intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 after dosing up to Day 60
- Pharmacokinetics (PK): Maximum Measured Plasma Concentration (Cmax) Of Total GAA And rhGAA Protein In Plasma In Participants With Pompe DiseaseTime frame: Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 hours, and 3 or 7 days postdose during Periods 1 and 2, and 24 to 30 days postdose during Period 2
- PK: Time To The Maximum Plasma Concentration (Tmax) Of Total GAA And rhGAA Protein In Plasma In Participants With Pompe DiseaseTime frame: Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 hours, and 3 or 7 days postdose during Periods 1 and 2, and 24 to 30 days postdose during Period 2
- PK: Elimination Half-life (T1/2) Of Total GAA And rhGAA Protein In Plasma In Participants With Pompe DiseaseTime frame: Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 hours, and 3 or 7 days postdose during Periods 1 and 2, and 24 to 30 days postdose during Period 2
- PK: Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Time Of The Last Measurable Concentration (AUC0-t) Of Total GAA And rhGAA Protein In Plasma In Participants With Pompe DiseaseTime frame: Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 hours, and 3 or 7 days postdose during Periods 1 and 2, and 24 to 30 days postdose during Period 2
- PK: AUC From Time 0 Extrapolated To Infinity (AUCinf) Of Total GAA And rhGAA Protein In Plasma In Participants With Pompe DiseaseTime frame: Predose, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 hours, and 3 or 7 days postdose during Periods 1 and 2, and 24 to 30 days postdose during Period 2
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Orange, California
Site not named
Gainesville, Florida
Site not named
Decatur, Georgia
Site not named
Kansas City, Kansas
Site not named
Great Falls, Montana
Site not named
Durham, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Portland, Oregon
Site not named
Springfield, Virginia
Site not named
Hamilton, Ontario, Canada
Site not named
Paris, France
Site not named
Salford, United Kingdom
Site not named
London, Queen Square, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.